|By PR Newswire||
|April 28, 2014 03:01 AM EDT||
SINGAPORE, April 28, 2014 /PRNewswire/ -- Moleac, a revenue-generating Biopharma company focused on stroke recovery, announced today the appointment of Mr Elmar Schnee as non-executive Chairman of the company.
Elmar Schnee succeeds to Prof Marc Vasseur, co-founder of Moleac and first Chairman (2004-2013).
Mr. Schnee was from 2011 - 2013 CEO of Cardiorentis in Zug, Switzerland. Prior to this, Mr. Schnee was General Partner and member of the Executive Board of Merck KGaA, responsible for its worldwide pharmaceutical business in Rx and OTC with sales of € 6 Billion and 18,000 employees until June 2011. He also led the major restructuring of the business in acquiring Serono for € 10.3 billion and selling the Generic Division for € 4.9 billion. Mr. Schnee led the successful integration into Merck Serono as CEO until end of 2010.
Mr. Schnee joined Merck KGaA in 2003 as President for France. He was promoted to Head of Global Ethical Pharmaceuticals and in 2005 elected as General Partner and Member of the Executive Board.
Prior Mr. Schnee held senior roles in Marketing, Strategy and Business Development in UCB Brussels, Sanofi-Synthelabo in Paris, Migliara Kaplan in Baltimore and Fisons in UK.
Mr. Schnee is currently a Director of Gentium SpA, Cardiorentis AG and Anecova SA.
Elmar Schnee said:
"I am very excited to join Moleac as Chairman and work together with the board and management to further develop NeuroAiD. Moleac has unique knowledge in the area of stroke recovery and NeuroAiD has proven already its utility in supporting stroke patients recovering faster and better. There is a great need for new drugs supporting stroke patients and I recognise the potential of Moleac to develop new drugs in this high need indication."
David Picard CEO of Moleac said:
"Moleac has provided already a therapeutic solution to thousands of stroke survivors with NeuroAiD. It now aims to deliver a stroke treatment which will enable an even larger number of patients to benefit from its knowhow. We welcome the wide experience that Elmar brings to Moleac in pharmaceutical development and operations, to take Moleac through the second stage of its rapid development to answer the needs of the stroke sufferers."
Moleac is a biopharmaceutical company founded in 2003 in Singapore, dedicated in finding and developing new medicines for the unmet needs of patients worldwide. Its development model combines a modern clinical approach and the latest biotechnologies.
NeuroAiD™ is the first stroke treatment that helps patients recover faster and a better from stroke disabilities while combined to a rehabilitation program. NeuroAiD™ is derived from natural components, carefully selected for their efficacy and safe use. It currently reaches out to patients in over 25 countries.
For further information, please contact Olfa Khechine, Global Marketing Manager, Moleac Singapore
Tel: (+65) 6211 3710 - Ext. 124
Email: [email protected]
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the nature of the communications. Does there really need to be only one protocol to rule them all? Of course not. In his session at @ThingsExpo, Chris Matthieu, co-founder and CTO of Octoblu, walk you through how Oct...
Oct. 1, 2016 03:00 AM EDT Reads: 2,433
There is growing need for data-driven applications and the need for digital platforms to build these apps. In his session at 19th Cloud Expo, Muddu Sudhakar, VP and GM of Security & IoT at Splunk, will cover different PaaS solutions and Big Data platforms that are available to build applications. In addition, AI and machine learning are creating new requirements that developers need in the building of next-gen apps. The next-generation digital platforms have some of the past platform needs a...
Oct. 1, 2016 03:00 AM EDT Reads: 1,963
Oct. 1, 2016 02:30 AM EDT Reads: 3,026
Oct. 1, 2016 02:30 AM EDT Reads: 2,714
Oct. 1, 2016 02:30 AM EDT Reads: 646
Oct. 1, 2016 02:30 AM EDT Reads: 522
Oct. 1, 2016 02:15 AM EDT Reads: 757
Oct. 1, 2016 02:15 AM EDT Reads: 5,456
Oct. 1, 2016 02:15 AM EDT Reads: 2,123
Oct. 1, 2016 02:15 AM EDT Reads: 516
Oct. 1, 2016 01:45 AM EDT Reads: 510
Oct. 1, 2016 01:15 AM EDT Reads: 721
Oct. 1, 2016 01:15 AM EDT Reads: 3,045
Oct. 1, 2016 12:15 AM EDT Reads: 1,428
Sep. 30, 2016 11:30 PM EDT Reads: 774